NR1H4 and metabolic dysfunction-associated steatotic liver disease: The tissue specific FXR modulation, namely, activation by quercetin/isorhamnetin in the liver and inhibition by isoquercitrin in the gut, highlights a fragmented mechanistic landscape where the structural determinants of this selectivity are poorly defined, which in turn is a major barrier to the rational design of targeted NAFLD therapeutics.